Detail akcie Prelude Therap Rg online

Business Summary: Prelude Therapeutics Incorporated is a clinical-stage fully integrated oncology company built on a foundation of drug discovery to deliver novel precision cancer medicines to underserved patients. It has developed a diverse pipeline consisting of multiple distinct programs: kinases, targeted protein degraders, and precision antibody drug conjugates. Its product candidates include PRT3789, PRT2527 and PRT7732. PRT3789 is a highly selective degrader of SMARCA2 protein, which, along with SMARCA4, controls gene regulation through chromatin remodeling. Its CDK9 program is an essential regulator of cancer-promoting transcriptional programs, including those driven by MCL1, MYC and MYB. PRT2527 is designed to be a potent and selective CDK9 inhibitor that has the potential to avoid off-target toxicities observed with other less selective CDK9 inhibitor. PRT7732 is a highly selective and orally bioavailable SMARCA2 degrader.
Financial Summary: BRIEF: For the nine months ended 30 September 2025, Prelude Therapeutics Inc revenues increased from $3M to $6.5M. Net loss decreased 16% to $83M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Medical Services segment loss decrease of 71% to $20.4M. Basic Earnings per Share excluding Extraordinary Items increased from -$1.30 to -$1.09.